![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Reddy will leverage the NRT portfolio, which includes Nicotinell (nicotine) in various formats such as lozenges, patches, and gum, across all applicable global market.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Nicotinell
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: $632.9 million Upfront Cash: $579.8 million
Deal Type: Acquisition June 26, 2024